We were privileged to hear visionary insights during Mike Ward’s fascinating fireside chat with Werner Lanthaler, CEO of Evotec. In the discussion, he asked Werner to share his views about the sector and big macro issues, as well as what it takes to build a biotech. This is what we learned: The teenage Werner wanted […]
Cambridge, UK, 20th October 2022: Enhanc3D Genomics (“Enhanc3D”), a functional genomics company unlocking the full potential of the human 3D genome to transform therapeutic development, today announces it has raised £10 million in Series A financing to accelerate the development of its proprietary technology platform – “GenLink3DTM”. The financing was led by BGF and Parkwalk Advisors, […]
AMSTERDAM, THE NETHERLANDS October 18th, 2022 — Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that it has signed a licensing agreement with Cristal Therapeutics to gain access to its CliCr® metal-free click chemistry. Read more…
BioInnovation Institute (BII) announces that it has entered a collaboration with Imperial College London (ICL) to launch a new translational project under its Bio Studio program. The program aims to foster the creation of new life science start-ups based on research from world-class scientists to benefit people and society. Read more…
BioInnovation Institute (BII), an international commercial non-profit foundation incubating and accelerating world-class life science research, today announces the latest cohort of participants in its Venture Lab acceleration program for early-stage companies. The cohort consists of nine ventures plus two corporate-sponsored innovation projects from Novo Nordisk – all strategically aligned with BII’s focus on developing ground-breaking scientific initiatives […]
